The extension granted by Nasdaq provides Oncternal Therapeutics with more time to regain compliance with the minimum bid requirement. This could potentially prevent the company's stock from being delisted, which would likely have a negative impact on the stock price. Therefore, this news could stabilize the stock in the short term.